Item 8.01. Other Events.

On November 8, 2021, the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the previously reported Collaboration and License Agreement (the "Collaboration and License Agreement") between REGENXBIO Inc. (the "Company") and AbbVie Global Enterprises Ltd. (the "Partner"), a subsidiary of AbbVie Inc. On November 9, 2021, the Collaboration and License Agreement closed.

Item 7.01. Regulation FD Disclosure.

On November 9, 2021, the Company issued a press release announcing the closing of the Collaboration and License Agreement. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits




Exhibit No.       Description

99.1                Press release dated November 9, 2021.

104               The cover page from this Current Report on Form 8-K, formatted in
                  Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses